Key result
Balloon-expandable valves had higher rates of structural valve deterioration (OR 2.09; 95% CI 1.58-2.75) and bioprosthetic valve failure (OR 1.61; 95% CI 1.10-2.36) than self-expanding valves.
Why the study?
TAVR is increasingly performed in younger patients with long life expectancy, but limited data exist regarding the comparative long-term durability of transcatheter heart valves.
Does balloon-expandable transcatheter heart valves reduce structural valve deterioration and bioprosthetic valve failure compared to self-expanding valves in patients undergoing TAVR?
Meta-Analysis (n=12,131)
Does balloon-expandable transcatheter heart valves reduce structural valve deterioration and bioprosthetic valve failure compared to self-expanding valves in patients undergoing TAVR?
Effect estimate: OR 2.09 (95% CI 1.58-2.75)
p-value: p=<0.001
At long-term follow-up (median 7 years), balloon-expandable valves were associated with higher rates of structural valve deterioration and bioprosthetic valve failure compared to self-expanding valves, with no difference in all-cause death.
May favor self-expanding valves for TAVR durability; extends meta-analytic evidence on long-term structural deterioration differences.
Background Transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) is increasingly performed in younger patients with long life expectancy. However, limited data exist on the durability of transcatheter heart valves (THVs). Aims The aim of the present work is to compare the long‐term durability of balloon‐expandable (BEV) and self‐expanding (SEV) THVs after TAVR. Methods Electronic databases were searched up to May 2025 for studies reporting on the long‐term durability of THVs in patients undergoing TAVR with a minimum follow‐up of 5 years. Pooled odds ratios (ORs) with 95% confidence interval (CI) were used as summary statistics and were calculated using a random‐effects model. Co‐primary endpoints were moderate and severe structural valve deterioration (SVD) and the occurrence of all‐cause bioprosthetic valve failure (BVF). All‐cause death was the secondary endpoint. Results A total of 22 studies and 12,131 patients undergoing TAVR were included: 52.5% of patients ( n = 6362) received BEV, 47.5% ( n = 5769) SEV. An old‐generation THV was used in 84.5% of cases. At a median follow‐up of 7 (5−8.3) years, the overall pooled estimates of moderate/severe SVD and BVF were 7% (5−9) and 4% (3−5), respectively. Patients treated with a BEV experienced a higher rate of SVD (OR: 2.09; 95% CI: 1.58−2.75; p < 0.001) and BVF (OR: 1.61; 95% CI: 1.10−2.36; p = 0.014); no difference was observed in terms of all‐cause death. Conclusions At long‐term follow‐up after TAVR, patients receiving a BEV experienced higher rates of moderate/severe SVD and of BVF compared to those having a SEV. However, no significant differences between the two THV designs were observed on the clinical endpoint of all‐cause death.
No takes yet. Share an insight, caveat, or question.
Continisio et al. (2025) conducted a meta-analysis in aortic stenosis (n=12,131). Balloon-expandable transcatheter heart valves vs. Self-expanding transcatheter heart valves was evaluated on Moderate and severe structural valve deterioration (SVD) (OR 2.09, 95% CI 1.58-2.75, p=<0.001). Balloon-expandable valves had higher rates of structural valve deterioration (OR 2.09; 95% CI 1.58-2.75) and bioprosthetic valve failure (OR 1.61; 95% CI 1.10-2.36) than self-expanding valves.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: